Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FPR1 | P21462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23479933 | 0.94 | TSHR (0.50) | MAPK13MAPK12MAPK11MAPK14TSHR | |
| Hydrochloric Acid SCHEMBL23202498 | 0.93 | TSHR (0.49) | MAPK13MAPK12MAPK11MAPK14TSHR | |
| Hydrochloric Acid SCHEMBL31096515 | 0.93 | TSHR (0.49) | MAPK13MAPK12MAPK11MAPK14TSHR | |
| SCHEMBL23479890 | 0.89 | ALOX15 (0.50) | ALDH1A1MEN1HTTKMT2AKDM4E | |
| SCHEMBL23479866 | 0.88 | ALOX15 (0.52) | ALDH1A1MEN1HTTKMT2AKDM4E | |
| SCHEMBL23479912 | 0.84 | SIGMAR1 (0.48) | TSHRALDH1A1MEN1HTTKMT2A | |
| SCHEMBL23479897 | 0.83 | SIGMAR1 (0.50) | TSHRALDH1A1MEN1HTTKMT2A | |
| SCHEMBL23479913 | 0.81 | KDM4E (0.41) | TSHRALDH1A1MEN1HTTKMT2A | |
| SCHEMBL23479858 | 0.81 | L3MBTL1 (0.44) | TSHRALDH1A1HTTMETKDM4E | |
| SCHEMBL23479895 | 0.78 | PDE4A (0.45) | HIF1AALDH1A1MEN1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702403-B2 | EAAT2 activators and methods of using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702403-B2 | EAAT2 activators and methods of using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230138663-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230138663-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210171497-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702403-B2 | EAAT2 activators and methods of using thereof | SLC1A2, SLC1A1, SLC18A2 | MAPK13 4008/4885MAPK12 4153/4885MAPK11 3833/4885 |
| US-20230138663-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | SLC1A2, SLC1A1, SLC18A2 | MAPK13 4008/4885MAPK12 4153/4885MAPK11 3833/4885 |
| US-20210171497-A1 | EAAT2 ACTIVATORS AND METHODS OF USING THEREOF | SLC1A2, SLC1A1, SLC18A2 | MAPK13 4008/4885MAPK12 4153/4885MAPK11 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.